MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry - Seite 2

Chief Executive Officer of MindBio, Justin Hanka said "Microdosing MB22001 is a disruptive treatment methodology that we know improves sleep, depression and mood and our ambition is to develop this treatment globally at scale for affordable access to patients without the limitations and side-effects of common anti-depressants.".

The Company currently has two Phase 2 clinical trials underway and new trials in development.

To read the published sleep research, go here: https://www.nature.com/articles/s41398-024-02900-4

Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=tr ...

Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

For further information, please contact:

Justin Hanka, Chief Executive Officer
61 433140886
[e-mail]

Media Inquiries

Kristina Spionjak
[e-mail]

About MindBio Therapeutics

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio's lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy partipicipants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.